canSAR: update to the cancer translational research and drug discovery knowledgebase
Nucleic Acids Research · 06.01.2023 · 51 (D1) · D1212-D1219
DOI: 10.1093/nar/gkac1004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 29.11.2022. Verfasst von Patrizio di Micco und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Genomic Medicine & The Institute of Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Drug Discovery, Knowledge Bases, Translational Research, Biomedical, Antineoplastic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Wellcome Trust, ‘canSAR: enhancing the drug discovery knowledgebase’.
Abstract (Originalsprache)
canSAR (https://cansar.ai) is the largest public cancer drug discovery and translational research knowledgebase. Now hosted in its new home at MD Anderson Cancer Center, canSAR integrates billions of experimental measurements from across molecular profiling, pharmacology, chemistry, structural and systems biology. Moreover, canSAR applies a unique suite of machine learning algorithms designed to inform drug discovery. Here, we describe the latest updates to the knowledgebase, including a focus on significant novel data. These include canSAR’s ligandability assessment of AlphaFold; mapping of fragment-based screening data; and new chemical bioactivity data for novel targets. We also describe enhancements to the data and interface.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Department of Genomic Medicine & The Institute of Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA.
- The Department of Data Science, The Institute of Cancer Research, London, UK.
- Centre for Cancer Drug Discovery, The Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
ORCID-Profile: Patrizio di Micco, Albert A Antolin, Paul Workman, Bissan Al-Lazikani
Förderung
- Cancer Research UK
- Wellcome Trust
- ‘canSAR: enhancing the drug discovery knowledgebase’
- CPRIT
- CRUK
- Chordoma Foundation
- Mark Foundation
- Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship
Zitieren
APA
di Micco, P., Antolin, A. A., Mitsopoulos, C., Villasclaras-Fernandez, E., Sanfelice, D., Dolciami, D., Ramagiri, P., Mica, I. L., Tym, J. E., Gingrich, P. W., Hu, H., Workman, P., & Al-Lazikani, B. (2023). canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 51(D1), D1212-D1219. https://doi.org/10.1093/nar/gkac1004
Vancouver
di Micco P, Antolin AA, Mitsopoulos C, Villasclaras-Fernandez E, Sanfelice D, Dolciami D, et al. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research. 2023;51(D1):D1212-D1219. doi:10.1093/nar/gkac1004
BibTeX
@article{diMicco2023,
author = {di Micco, Patrizio and Antolin, Albert A and Mitsopoulos, Costas and Villasclaras-Fernandez, Eloy and Sanfelice, Domenico and Dolciami, Daniela and Ramagiri, Pradeep and Mica, Ioan L and Tym, Joseph E and Gingrich, Philip W and Hu, Huabin and Workman, Paul and Al-Lazikani, Bissan},
title = {canSAR: update to the cancer translational research and drug discovery knowledgebase},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {D1},
pages = {D1212--D1219},
doi = {10.1093/nar/gkac1004}
}
EUVIMED